Valuation: Lundbeck

Market Cap 41.34B 6.44B 5.53B 5.19B 4.74B 8.95B 615B 8.99B 61.44B 23.81B 310B 24.2B 23.67B 1,027B P/E 2026 *
9.39x
P/E 2027 * 9.22x
Enterprise Value 45.35B 7.07B 6.07B 5.69B 5.2B 9.81B 674B 9.86B 67.39B 26.11B 340B 26.54B 25.96B 1,126B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.58x
Free-Float
30.74%
Yield 2026 *
3.64%
Yield 2027 * 3.27%
1 day-1.66%
1 week+12.21%
Current month+14.86%
1 month+14.70%
3 months+15.83%
6 months+18.48%
Current year+14.23%
1 week 40.1
Extreme 40.1
42.6
1 month 35.1
Extreme 35.1
42.6
Current year 31.4
Extreme 31.4
42.6
1 year 31.4
Extreme 31.4
42.6
3 years 23.3
Extreme 23.3
42.6
5 years 21.94
Extreme 21.935
42.6
10 years 21.94
Extreme 21.935
42.6
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-2.13%+12.21% - - 6.59B
-0.93%+5.05%+31.78%+111.80% 106B
+0.20%+1.51%+61.64%+165.66% 55.33B
-0.70%-2.07%+0.71%+261.78% 23.53B
+1.11%-0.37%-15.97%-12.04% 8.13B
+0.48%-5.74%-40.91%-26.27% 7.12B
+1.07%-4.67%-19.04%-26.22% 6.35B
-2.06%-4.78%+7.07%+21.44% 6.59B
-1.26%+1.67%-2.60%+19.10% 5.17B
+0.93%+7.24%+240.52%+385.04% 3.84B
Average -0.23%+0.48%+29.24%+100.03% 24.62B
Weighted average by Cap. -0.47%+0.84%+32.47%+128.13%

Financials

2026 *2027 *
Net sales 25.92B 4.04B 3.47B 3.25B 2.97B 5.61B 385B 5.64B 38.52B 14.93B 194B 15.17B 14.84B 644B 26.05B 4.06B 3.49B 3.27B 2.99B 5.64B 387B 5.67B 38.72B 15B 195B 15.25B 14.92B 647B
Net income 4.59B 715M 614M 576M 526M 993M 68.18B 997M 6.82B 2.64B 34.4B 2.68B 2.63B 114B 4.65B 725M 622M 584M 533M 1.01B 69.11B 1.01B 6.91B 2.68B 34.86B 2.72B 2.66B 115B
Net Debt 4B 624M 536M 503M 459M 866M 59.51B 871M 5.95B 2.31B 30.02B 2.34B 2.29B 99.44B -178M -27.7M -23.77M -22.32M -20.38M -38.46M -2.64B -38.65M -264M -102M -1.33B -104M -102M -4.41B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-08-26 DKK 41.35 -2.13% 80,250
26-08-25 DKK 42.25 +3.05% 227,799
26-08-24 DKK 41.00 +1.23% 127,581
26-08-21 DKK 40.50 +0.50% 120,723
26-08-20 DKK 40.30 -3.93% 261,361
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
41.80DKK
Average target price
48.73DKK
Spread / Average Target
+16.58%

Quarterly revenue - Rate of surprise